Aligos Therapeutics signs license deal to develop pevifoscorvir in China

Aligos Therapeutics (ALGS) has entered into an exclusive license agreement to develop and commercialize pevifoscorvir sodium with Xiamen Amoytop in Greater China, which includes Mainland China, Taiwan, Hong Kong, and Macau for chronic hepatitis B virus, or HBV, infection. Aligos will receive an upfront milestone of $25M and is eligible to receive up to $420M in clinical, regulatory, and sales milestones along with tiered, high single-digit royalties on net sales in Amoytop’s licensed territories. Aligos retains all development and commercialization rights for pevifoscorvir sodium in the U.S., Europe, South Korea, Japan, and all other markets. In addition, Aligos will retain the right to conduct clinical trials in Greater China. As a result of this agreement, Aligos expects that current cash, cash equivalents and investments will be extended into Q4 based on the current operating plan. Pevifoscorvir sodium is a potential first and best-in-class capsid assembly modulator under development for chronic HBV infection. Pevifoscorvir sodium is currently being evaluated in the Phase 2 study vs. the nucleoside analog, tenofovir disoproxil fumarate, with the second interim analysis expected in the second half of 2026 and topline data planned for 2027. The closing of this transaction is conditional and automatically effective upon Amoytop receiving approval at a Shareholders’ Meeting, which is anticipated within 30 days.